Nilotinib works by inhibiting the abnormal BCR::ABL kinase that drives CML, helping to reduce leukemia cell proliferation. Its targeted mechanism allows it to remain effective against several mutations associated with reduced response to imatinib.2
Nilotinib overcomes imatinib resistance resulting from BCR::ABL kinase mutations.3
Learn more about CAVHANZA.
Treating Ph+ CML with CAVHANZA
References
1. National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 1.2026, 16 July 2025. Available at: https://www.hematology.org.il/wp-content/uploads/2025/08/cml.pdf. [Accessed: February 26 2026].
2. Blood Cancer UK. (2025). Tyrosine kinase inhibitors (TKIs). [online]. Available at: https://bloodcancer.org.uk/understanding-blood-cancer/leukaemia/chronic-myeloid-leukaemia-cml/cml-treatment-side-effects/tyrosine-kinase-inhibitors/. [Accessed: March 26 2026].
3. CAVHANZA™ (nilotinib) Orally Disintegrating Tablets. Prescribing Information. Flex Pharma.

